局部前列腺癌二十次分割的MRI引导放射治疗:MOMENTUM研究结果
基于国际多中心MOMENTUM注册研究,分析146例在1.5 T MR-Linac上接受60 Gy/20次根治性MRI引导放射治疗的局限期前列腺癌患者,评估2年毒性、早期生化反应和患者报告结局。结果显示3个月≥2级胃肠毒性为3%、≥2级泌尿生殖毒性为7%,12个月中位PSA显著下降;前6个月生活质量下降(EORTC评分平均降低11.4分,具临床意义),24个月恢复至基线;作者认为该方案可行、毒性低,但MRIgRT相较常规放疗的临床优势在中度大分割下不明显。
要点
- 146例局限期前列腺癌患者接受1.5 T MR-Linac 60 Gy/20次MRI引导放疗。
- 3个月≥2级胃肠毒性和泌尿生殖毒性分别为3%和7%。
- 前6个月生活质量下降,EORTC评分平均降低11.4分,24个月恢复至基线。
核心结论
- 本研究证实了在1.5 T MR-Linac上对局限期前列腺癌实施在线MRI引导放射治疗的可行性,毒性发生率低,与文献已发表结果相似。
- 在中度大分割背景下,MRIgRT相较常规放疗的临床获益尚不明显。
- 作者指出进一步研究将聚焦超大分割方案,MRIgRT对前列腺癌的潜在优势可能更易显现。
研究设计与样本
- 研究为国际多中心注册研究MOMENTUM的一部分,纳入2018年11月至2022年6月期间在1.5 T MR-Linac上接受根治性MRI引导放疗(60 Gy/20次)的局限期前列腺癌患者146例。
- 随访时测量PSA水平和CTCAE 5.0版毒性数据;同意患者报告结局采集的患者完成EQ-5D-5L、EORTC QLQ-C30和EORTC QLQ-PR25问卷。
主要发现
- 3个月时≥2级胃肠毒性发生率为3%,≥2级泌尿生殖毒性发生率为7%。
- 12个月时中位PSA显著下降。
- EQ-5D-5L数据和EORTC总体健康状况量表均提示前6个月生活质量下降;EORTC量表评分平均变化为降低11.4分,被认为具有临床重要性。
- 生活质量在24个月时恢复至基线;激素症状前6个月加重、24个月恢复至基线;所有男性的性活动前3个月恶化、12个月恢复至基线。
关键数值与推荐
- 放疗方案为60 Gy分20次。
- 毒性分级采用CTCAE 5.0版。
- 患者报告结局采用EQ-5D-5L、EORTC QLQ-C30和EORTC QLQ-PR25问卷评估。
临床怎么用
- 原文结论指出本研究证实了在线MRIgRT在1.5 T MR-Linac上治疗局限期前列腺癌的可行性,毒性发生率低。
- 原文结论指出在中度大分割背景下MRIgRT相较常规放疗的临床获益尚不明显。
- 原文未据此给出具体临床推荐。
局限性
- 原文结论指出在中度大分割背景下MRIgRT相较常规放疗的临床获益尚不明显。
- 原文结论指出进一步研究将聚焦超大分割方案,以观察MRIgRT对前列腺癌的潜在优势是否更易显现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: MRI-guided radiotherapy (MRIgRT) offers multiple potential advantages over CT-guidance. This study examines the potential clinical benefits of MRIgRT for men with localised prostate cancer, in the setting of moderately hypofractionated radiotherapy. We evaluate two-year toxicity outcomes, early biochemical response and patient-reported outcomes (PRO), using data obtained from a multicentre international registry study, for the first group of patients with prostate cancer who underwent treatment on a 1.5 T MR-Linac. MATERIALS AND METHODS: Patients who were enrolled within the MOMENTUM study and received radical treatment with 60 Gy in 20 fractions were identified. PSA levels and CTCAE version 5.0 toxicity data were measured at follow-up visits. Those patients who consented to PRO data collection also completed EQ-5D-5L, EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires. RESULTS: Between November 2018 and June 2022, 146 patients who had MRIgRT for localised prostate cancer on the 1.5 T MR-Linac were eligible for this study. Grade 2 and worse gastro-intestinal (GI) toxicity was reported in 3 % of patients at three months whilst grade 2 and worse genitourinary (GU) toxicity was 7 % at three months. There was a significant decrease in the median PSA at 12 months. The results from both the EQ-5D-5L data and EORTC global health status scale indicate a decline in the quality of life (QoL) during the first six months. The mean change in score for the EORTC scale showed a decrease of 11.4 points, which is considered clinically important. QoL improved back to baseline by 24 months. Worsening of hormonal symptoms in the first six months was reported with a return to baseline by 24 months and sexual activity in all men worsened in the first three months and returned to baseline at 12 months. CONCLUSION: This study establishes the feasibility of online-MRIgRT for localised prostate on a 1.5 T MR-Linac with low rates of toxicity, similar to that published in the literature. However, the clinical benefits of MRIgRT over conventional radiotherapy in the setting of moderate hypofractionation is not evident. Further research will focus on the delivery of ultrahypofractionated regimens, where the potential advantages of MRIgRT for prostate cancer may become more discernible.
引用
- Sritharan K, Daamen L, Pathmanathan A, et al. MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study. Clin Transl Radiat Oncol. 2024. PMID: 38440792. doi:10.1016/j.ctro.2024.100742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。